Monday, December 15, 2014

The Great Generic Drug Rip-Off

Big Pharma has followed the only avenue left to reap billion-dollar profits: jack up the price of generics.


What happens when rapacious cartels run out of billion-dollar-profit products? They jack up the price of what was previously low-cost. And why are they able to raise prices by 388% to 8,000% at will? Because they can. That's the whole point in having a cartel that is enabled and enforced by the cartel's toadies and apologists in the central state (federal government): price increases can be imposed on the government and the private sector at will.

I was alerted to the extraordinary price increases in widely used generic drugs by Ishabaka (M.D.), who forwarded this fact sheet issued by the office of Senator Bernie Sanders: (Chart is reproduced below)

"Rep. Elijah E. Cummings and Senator Bernard Sanders sent letters to 14 drug manufacturers requesting information about the escalating prices of generic drugs used to treat everything from common medical conditions to life-threatening illnesses. Data was provided by the Healthcare Supply Chain Association (HSCA) on recent purchases by group purchasing organizations (GPOs) of ten generic drugs."

Here are Ishabaka's comments:

"I'd like to focus on the top one - doxycycline. This is a very effective antibiotic for pneumonia, bronchitis, and sexually transmitted diseases (chlamydia and gonorrhea). Throughout my medical career, it has been a cheap generic drug I used all the time. It's cost has gone up from $20 a prescription to over $1,600 a prescription in the last 12 months.

Low-income people used to be able to afford doxycycline, which would stop the spread of these serious, sometimes life-threatening infections. Now they can't, and there is no drug as good as doxycycline available cheaply. I think this is an outrage. Imagine if a generic bottle of aspirin increased in price from $10 a bottle to $800 a bottle in 12 months - Americans would be marching in protest."

DrugUseAverage Market Price Oct. 2013Average Market Price April 2014Average Percentage Increase
Doxycycline Hyclate
(bottle of 500, 100 mg tablets)
antibiotic used to treat a variety of infections$20$1,8498,281%
Albuterol Sulfate
(bottle of 100, 2 mg tablets)
used to treat asthma and other lung conditions$11$4344,014%
Glycopyrrolate
(box of 10 0.2 mg/mL, 20 mL vials)
used to prevent irregular heartbeats during surgery$65$1,2772,728%
Divalproex Sodium ER
(bottle of 80, 500 mg tablets ER 24H)
used to prevent migraines and treat certain types of seizures$31$234736%
Pravastatin Sodium
(bottle of 500, 10 mg tablets)
used to treat high cholesterol and to prevent heart disease$27$196573%
Neostigmine Methylsulfate
(box of 10 1:1000 vials)
used in anesthesia to reverse the effects of some muscle relaxants$25$121522%
Benazepril/
Hydrochlorothiazide
(bottle of 100, 20-25 mg tablets)
used to treat high blood pressure$34$149420%
Isuprel
(box of 25, 0.2 mg/mL vials)
used to treat heart attacks and irregular heartbeat$916$4,489390%
Nitropress
(50 mg vial)
used to treat congestive heart failure and reduce blood pressure$44$215388%
Digoxin
(single tablet, 250 mcg)
used to treat irregular heartbeats and heart failure$0.11$1.10884%

The murky world of drug pricing is attracting some much-needed attention:



What politicos and the mainstream media cannot dare state openly is obvious: the system of drug development and generic drug pricing/distribution is broken in the U.S., and the core cause is the cartel-like structure of Big Pharma and the rest of the healthcare system.

Though nobody in officialdom or the mainstream media can say this publicly, the reason for these outrageous increases is painfully obvious: As Big Pharma's stable of billion-dollar drugs slip off patent, their profit pipeline is weakening.

The pipeline of potentially billion-dollar-profit drugs (so-called blockbuster drugs) is thin. So Big Pharma has followed the only avenue left to reap billion-dollar profits: jack up the price of generics, and push the government to pay the outrageous increases via Medicare and Medicaid and force the increases on private insurers and providers. If we just roll over and accept 8,000% increases, we deserve the corrupt, rapacious system we have. 



Get a Job, Build a Real Career and Defy a Bewildering Economy(Kindle, $9.95)(print, $20)
go to Kindle editionAre you like me? Ever since my first summer job decades ago, I've been chasing financial security. Not win-the-lottery, Bill Gates riches (although it would be nice!), but simply a feeling of financial control. I want my financial worries to if not disappear at least be manageable and comprehensible.

And like most of you, the way I've moved toward my goal has always hinged not just on having a job but a career.
You don't have to be a financial blogger to know that "having a job" and "having a career" do not mean the same thing today as they did when I first started swinging a hammer for a paycheck.

Even the basic concept "getting a job" has changed so radically that jobs--getting and keeping them, and the perceived lack of them--is the number one financial topic among friends, family and for that matter, complete strangers.


So I sat down and wrote this book: Get a Job, Build a Real Career and Defy a Bewildering Economy.


It details everything I've verified about employment and the economy, and lays out an action plan to get you employed.


I am proud of this book. It is the culmination of both my practical work experiences and my financial analysis, and it is a useful, practical, and clarifying read.


Test drive the first section and see for yourself.     Kindle, $9.95     print, $20


"I want to thank you for creating your book Get a Job, Build a Real Career and Defy a Bewildering Economy. It is rare to find a person with a mind like yours, who can take a holistic systems view of things without being captured by specific perspectives or agendas. Your contribution to humanity is much appreciated."
Laura Y.

Gordon Long and I discuss The New Nature of Work: Jobs, Occupations & Careers(25 minutes, YouTube) 



NOTE: Contributions/subscriptions are acknowledged in the order received. Your name and email remain confidential and will not be given to any other individual, company or agency.


Thank you, Christopher M. ($5/month), for your monstrously generous subscription to this site-- I am greatly honored by your support and readership.

Terms of Service

All content on this blog is provided by Trewe LLC for informational purposes only. The owner of this blog makes no representations as to the accuracy or completeness of any information on this site or found by following any link on this site. The owner will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information. These terms and conditions of use are subject to change at anytime and without notice.


Our Privacy Policy:


Correspondents' email is strictly confidential. This site does not collect digital data from visitors or distribute cookies. Advertisements served by a third-party advertising network (Investing Channel) may use cookies or collect information from visitors for the purpose of Interest-Based Advertising; if you wish to opt out of Interest-Based Advertising, please go to Opt out of interest-based advertising (The Network Advertising Initiative). If you have other privacy concerns relating to advertisements, please contact advertisers directly. Websites and blog links on the site's blog roll are posted at my discretion.


PRIVACY NOTICE FOR EEA INDIVIDUALS


This section covers disclosures on the General Data Protection Regulation (GDPR) for users residing within EEA only. GDPR replaces the existing Directive 95/46/ec, and aims at harmonizing data protection laws in the EU that are fit for purpose in the digital age. The primary objective of the GDPR is to give citizens back control of their personal data. Please follow the link below to access InvestingChannel’s General Data Protection Notice. https://stg.media.investingchannel.com/gdpr-notice/


Notice of Compliance with The California Consumer Protection Act
This site does not collect digital data from visitors or distribute cookies. Advertisements served by a third-party advertising network (Investing Channel) may use cookies or collect information from visitors for the purpose of Interest-Based Advertising. If you do not want any personal information that may be collected by third-party advertising to be sold, please follow the instructions on this page: Limit the Use of My Sensitive Personal Information.


Regarding Cookies:


This site does not collect digital data from visitors or distribute cookies. Advertisements served by third-party advertising networks such as Investing Channel may use cookies or collect information from visitors for the purpose of Interest-Based Advertising; if you wish to opt out of Interest-Based Advertising, please go to Opt out of interest-based advertising (The Network Advertising Initiative) If you have other privacy concerns relating to advertisements, please contact advertisers directly.


Our Commission Policy:

As an Amazon Associate I earn from qualifying purchases. I also earn a commission on purchases of precious metals via BullionVault. I receive no fees or compensation for any other non-advertising links or content posted on my site.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP